Call for Public Review: Updated Guidance on Inclusive Language in Medical and Scientific Publications

Sep 17, 2024 | Health research

In the realm of medical and scientific publishing, the precision and respect embedded in our language are crucial. The choice of terminology when describing individuals and groups can profoundly influence the clarity and fairness of our communications. Inclusive language is not merely a stylistic preference but a fundamental aspect of respectful and accurate representation.

To advance these principles, the AMA Manual of Style committee has revised its guidance on the use of inclusive language, focusing on gender, sex, gender identity, sexual orientation, and age. This updated draft is designed to help authors and editors navigate the complex landscape of demographic reporting with sensitivity and consistency.

Key Highlights of the Updated Guidance:

The revised guidance addresses several critical areas to ensure respectful and accurate language use:

  • Inclusive Language Overview: Provides an introduction to the principles of inclusive language, emphasising the importance of avoiding reductionist descriptions and recognising the intersectionality of different characteristics.
  • Concerns and Controversies: Explores ongoing debates and challenges in the use of inclusive language within healthcare and research contexts.
  • Glossary and Definitions: Offers clear definitions of terms related to gender, sex, gender identity, and sexual orientation to promote accurate and consistent usage.
  • Reporting Guidance: Details best practices for reporting demographic characteristics in research articles, including the presentation of data in tables and figures.
  • Practical Examples: Includes examples of commonly used terms and their appropriate contexts to guide authors in their writing.
  • Grammar and Usage: Addresses grammar and punctuation concerns specific to gender, sex, gender identity, and sexual orientation, including recommendations for gender-neutral terms and personal pronouns.
  • Age and Other Considerations: Provides guidance on the respectful and accurate reporting of age and other demographic factors.

We invite our community at Pharmalys to contribute to the development of this important guidance by reviewing the draft and providing feedback. Your insights are invaluable in ensuring that the recommendations are clear, fair, and effective. The draft guidance is available for review at https://jamanetwork.com/pages/draft-guidance until September 30, 2024.

We appreciate your participation in this review process to ensure inclusivity within all future Medical and Scientific Publications.

Milena Henderson, for Pharmalys Communication Department

Newsletter September 2024

Newsletter September 2024

A Year of Growth and Discovery: Reflections from a Clinical Project Manager at Pharmalys Ltd Pharmalys Ltd is a regional Contract Research Organisation (CRO) that has seen significant growth over the past three years. Headquartered in Europe with regional offices in...

Newsletter July 2024

Newsletter July 2024

Pharmalys Ltd: Our Commitment to Quality As an international Contract Research Organisation (CRO), Pharmalys Ltd has always been dedicated to delivering excellence in every service we provide, ensuring quality at every step. Our Business Excellence and Quality...

Our Soft Skills Training Programme was a huge success!

Our Soft Skills Training Programme was a huge success!

Since 2008, Pharmalys Ltd has seen consistent growth, with a notable acceleration over the past two years, expanding from 30 to 50 employees. The Pharmalys team is primarily composed of remote workers spread across the globe, from USA to India, the UK to South Africa....

Barriers to cancer clinical trials participation

Barriers to cancer clinical trials participation

Ongoing cancer clinical trials in Africa in 2020 From Unger J.M. et al. JNCI J Natl Cancer Inst 2019. * Circles represent individual clinical trials * Colors of the circles represent the study’s primary sponsor type   The cancer clinical trials context Clinical...

Pharmalys Ltd: Our Commitment to Quality

Pharmalys Ltd: Our Commitment to Quality

As an international Contract Research Organisation (CRO), Pharmalys Ltd has always been dedicated to delivering excellence in every service we provide, ensuring quality at every step. Our Business Excellence and Quality Management team is integral to all our services,...

Future prospects in clinical research

Future prospects in clinical research

Strategies for the future of clinical research: decentralised clinical trials Challenges with traditional clinical trials The traditional clinical trials system acts as a quality funnel for the development and implementation of new drugs, devices and health system...